

## Product Information

### Thrombin from bovine plasma

Catalog Number **T7513**  
Storage Temperature  $-20\text{ }^{\circ}\text{C}$

CAS RN 9002-04-4  
EC 3.4.21.5

Synonym: Factor IIa, FIIa, fibrinogenase, thrombase, tropostasin, activated blood-coagulation factor II  
EXPASY/SwissProt P00735

#### Product Description

Thrombin is an endolytic serine protease that selectively cleaves the Arg–Gly bonds of fibrinogen to form fibrin and release fibrinopeptides A and B.<sup>1,2</sup> The predominant form of thrombin *in vivo* is the zymogen prothrombin (factor II), which is produced in the liver. Prothrombin is a glycoprotein with a glycan content of ~12%.<sup>2</sup> Prothrombin is cleaved *in vivo* by activated factor X (factor Xa), releasing the activation peptide and cleaving thrombin into light and heavy chains, which yields catalytically active  $\alpha$ -thrombin.

Bovine  $\alpha$ -thrombin is composed of a light chain (A chain, MW ~5 kDa) and a heavy chain (B chain, MW ~33 kDa).<sup>3</sup> These two chains are joined by one disulfide bond. The B chain of bovine thrombin includes a carbohydrate portion of MW ~2.5 kDa, with *N*-linked glycosylation at Asn<sup>60</sup>.<sup>3</sup> Bovine thrombin contains 1.7% glucosamine, 1.8% sialic acid, 0.61% galactose, and 0.95% mannose.<sup>4</sup>

Thrombin also contains  $\gamma$ -carboxyglutamyl residues. These modified glutamyl residues are the result of carboxylation by vitamin K-dependent carboxylase, a microsomal enzyme.  $\gamma$ -Carboxyglutamyl residues are necessary for the  $\text{Ca}^{2+}$ -dependent interaction with a negatively charged phospholipid surface, which is essential for the conversion of prothrombin to thrombin.

Prothrombin is activated *in vivo* on the surface of a phospholipid membrane that binds the amino terminus of prothrombin along with factors Va and Xa. The activation process starts slowly because factor V is activated to factor Va by the initial, small amount of thrombin.

The optimal cleavage sites for thrombin are as follows:<sup>1</sup>

1. A-B-Pro-Arg-||-X-Y, where A and B are hydrophobic amino acids, and X and Y are nonacidic amino acids
2. Gly-Arg-||-Gly

Thrombin cleavage of fibrinogen occurs only at Arg residues. However, the cleavage is not site-specific, and generally results in 2 products:

- The primary cleavage product, fibrinopeptide A, is cleaved from fibrinogen after amino acid 16 and sometimes after amino acid 19.
- A secondary cleavage product, fibrinopeptide B, is produced by cleavage at amino acid 14.<sup>5</sup>

Thrombin from any mammalian species will clot the fibrinogen of any other mammalian species.<sup>6</sup> Thrombin does not require divalent metal ions or cofactors for activity. However,  $\text{Na}^{+}$ -dependent allosteric activation of thrombin has been shown to play a role in defining the primary specificity of thrombin to cleave after Arg residues.<sup>7</sup>

Thrombomodulin serves as a cofactor for thrombin during the activation of protein C.<sup>8</sup> Thrombin catalyzes the hydrolysis of several peptide *p*-nitroanilides, tosyl-Arg-nitrobenzyl ester, and thiobenzyl ester synthetic substrates.<sup>6</sup>

Under certain storage conditions, autolytic digestion of  $\alpha$ -thrombin results in formation of  $\beta$  and  $\gamma$ -thrombins, which lack fibrinolytic activity, but retain some activity against synthetic peptide substrates and protein substrates other than fibrinogen.<sup>9</sup> This thrombin preparation is predominantly  $\alpha$ -thrombin.

Catalytic pH range:<sup>10</sup> 5–10

Optimal pH:<sup>10</sup> 8.3

(Note: thrombin precipitates at  $\text{pH} \leq 5$ )

Bovine isozymes pI range:<sup>11</sup> 7.05–7.1

$E_{280}^{1\%}$ :<sup>12</sup> 19.5

This product is lyophilized from a solution containing saline and sodium citrate buffer, pH 6.5.

Specific Activity:  $\geq 2,000$  NIH units/mg protein  
( $E_{280}^{1\%} = 19.5$ )

Unit Definition: Activity is expressed in NIH units obtained by direct comparison to a NIH Thrombin Reference Standard. The NIH assay procedure uses 0.2 mL of diluted plasma (1:1 with saline) as a substrate and 0.1 mL of albumin solution based on a modification of the method of Biggs.<sup>13</sup> Only clotting times in the range of 15–25 seconds are used for determining thrombin activity. Optimal clotting temperature is 37 °C.

Thrombin concentrations in the literature are typically reported in terms of different units of activity.<sup>13,14</sup> Several conventions are used to express thrombin activity in the literature:

1 IOWA unit = 0.83 NIH unit  
1 WHO unit = 1 NIH unit  
1 NIH unit =  $0.324 \pm 0.073$   $\mu\text{g}$   
1 NIH unit = 1 USP unit

#### Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

#### Preparation Instructions

The product is soluble in water (10 mg/mL), yielding a clear solution.

#### Storage/Stability

Stock solutions can be prepared at a concentration of 100 units/mL in a 0.1% (w/v) BSA solution. Stock solutions remain active for one week at 0–5 °C. Solutions are most stable at pH 6.5, as a pH >7 will greatly reduce thrombin activity. Since thrombin solutions adsorb to glass, it is recommended to aliquot the solutions in plastic tubes and store at –20 °C for long-term storage.

Store the lyophilized powder at –20 °C.

#### References

1. Chang, J.Y., *Eur. J. Biochem.*, **151(2)**, 217-224 (1985).
2. Doolittle, R.F., in *The Plasma Proteins*, Volume II (Biosynthesis Metabolism, Alterations in Disease), 2nd ed. (Putnam, F.W., ed.). Academic Press (New York, NY), pp. 148-149 (1975).
3. Malkowski, M.G., *et al.*, *Protein Sci.*, **6(7)**, 1438-1448 (1997).
4. Magnusson, S., *The Enzymes* (Third Edition), Vol. III (Boyer, P.D., ed.), Academic Press (New York, NY), pp. 277-321 (1971).
5. Machovich, R. (ed.), *The Thrombin*, Vol. 1. CRC Press (Boca Raton, FL), pp. 63-66 (1984).
6. Lottenberg, R., *et al.*, *Meth. Enzymol.*, **80(Part C)**, 341-361 (1981).
7. Prasad, S., *J. Biol. Chem.*, **279(11)**, 10103-10108 (2004).
8. Kisiel, W., *J. Clin. Invest.*, **64(3)**, 761-769 (1979).
9. Boissel, J.P., *et al.*, *J. Biol. Chem.*, **259(9)**, 5691-5697 (1984).
10. Machovich, R. (ed.), *The Thrombin*, Vol. 1. CRC Press (Boca Raton, FL), p. 111 (1984).
11. Righetti, P.G., *et al.*, *J. Chromatogr. A*, **220(2)**, 115-194 (1981).
12. Winzor, D.J., and Scheraga, H.A., *Arch. Biochem. Biophys.*, **104(2)**, 202-207 (1964).
13. Biggs, R., ed., *Human Blood Coagulation, Haemostasis and Thrombosis* (2<sup>nd</sup> ed.), Blackwell Scientific Publications (Philadelphia, PA), p. 722 (1976).
14. Hemker, H.C., *Handbook of Synthetic Substrates for the Coagulation and Fibrinolytic System*, Martinus Nijhoff (Boston, MA) / Springer (Dordrecht, The Netherlands), pp. 95-101 (1983).

CS,RBG,GCY,MAM 01/18-1